CNS Pharmaceuticals (CNSP) said Tuesday it has acquired from Cortice Biosciences orphan drug designation for late stage abeotaxane TPI 287 as a potential treatment for glioblastoma multiforme.
The company said it aims to begin enrolling patients for a phase 2 study around the end of this year. Clinical data from a phase 1 trial showed that TPI 287 has the potential to cross the blood brain barrier and treat central nervous system tumors, according to the company.
TPI 287 was previously granted orphan drug designation by the US Food and Drug Administration in gliomas, pediatric neuroblastoma, and progressive supranuclear palsy, the company said.
The company's shares surged past 120% in recent Tuesday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.